文献速递腹部CT

多期动态CT无创识别增殖型肝细胞癌:定量测量与LI-RADS词典特征评估

Noninvasive identification of proliferative hepatocellular carcinoma on multiphase dynamic CT: quantitative and LI-RADS lexicon-based evaluation.
PubMed 文献 · Eur Radiol · 2024-12-12

回顾性分析两个医疗中心273例经手术证实的肝细胞癌患者(其中增殖型102例)的术前多期动态CT,按2021版LI-RADS通用词典评估影像特征并做定量测量,构建四种预测模型并在外部队列验证;联合模型(AFP≥200 ng/mL、环形动脉期高强化、肿瘤边缘不光滑、包膜不完整或缺失、门静脉期标准化肿瘤-主动脉密度比≤-0.13)训练队列AUC 0.871、验证队列AUC 0.870,作者认为该模型有望用于术前无创预测增殖型肝细胞癌,但需进一步验证。

要点

  • 联合模型纳入AFP≥200 ng/mL、环形动脉期高强化、边缘不光滑、包膜不完整或缺失及门静脉期标准化肿瘤-主动脉密度比≤-0.13。
  • 联合模型训练队列AUC 0.871,外部验证队列AUC 0.870。
  • AFP≥200 ng/mL与环形动脉期高强化与肝细胞癌复发显著相关(p<0.05)。

核心结论

  • 整合临床、CT定量与定性特征的联合模型对增殖型肝细胞癌的术前无创预测显示出潜力,但需进一步验证以确立其更广泛的临床实用性。

研究设计与样本

  • 回顾性分析两个医疗中心273例经手术证实的肝细胞癌患者(增殖型102例),术前均行多期动态CT,按2021版LI-RADS通用词典评估影像特征并分析定量测量,构建临床、CT定量-临床、CT定性-临床及联合四种预测模型并在外部队列验证,采用ROC分析评估模型性能,并在单病灶≤5 cm亚组(n=124)中测试所有模型。

诊断标准与关键数值

  • 联合模型包含AFP≥200 ng/mL、环形动脉期高强化、肿瘤边缘不光滑、包膜不完整或缺失三个定性特征,以及门静脉期标准化肿瘤-主动脉密度比≤-0.13一个定量特征;联合模型训练队列AUC 0.871、外部验证队列AUC 0.870;CT定量-临床模型与CT定性-临床模型在训练队列和外部验证队列的AUC均>0.79。

临床应用与阅片要点

  • 作者认为联合模型对增殖型肝细胞癌的术前无创预测显示出潜力,AFP≥200 ng/mL和环形动脉期高强化与肝细胞癌复发显著相关(p<0.05),可能为个体化治疗提供潜在指导。

局限性

  • 原文结论指出需进一步验证以确立该模型更广泛的临床实用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To identify proliferative hepatocellular carcinoma (HCC) preoperatively using quantitative measurements combined with the updated standard 2021 LI-RADS universal lexicon-based qualitative features on multiphase dynamic CT (MDCT).

METHODS: We retrospectively analyzed 273 patients (102 proliferative HCCs) who underwent preoperative MDCT with surgically confirmed HCC in two medical centers. Imaging features were evaluated according to the updated 2021 LI-RADS universal lexicon, and quantitative measurements were analyzed. All MDCT findings and clinical factors were compared. Four predictive models (clinical, CT quantitative-clinical, CT qualitative-clinical, and combinational models) were developed and validated in an external cohort for identifying proliferative HCC. ROC analysis was used to assess model performances. All models were tested in a subgroup of patients with a single lesion ≤ 5 cm (n = 124).

RESULTS: Both the CT quantitative-clinical and CT qualitative-clinical models effectively identified proliferative HCC in the training and external validation cohorts (all AUCs > 0.79). The combinational model, integrating one clinical (AFP ≥ 200 ng/mL), three qualitative (rim arterial phase hyperenhancement (APHE), non-smooth tumor margin, and incomplete or absent capsule), and one quantitative feature (standardized tumor-to-aorta density ratio in portal venous phase ≤ (- 0.13), showed significant improvement in the training cohort (AUC 0.871) and comparable performance in the validation cohort (AUC 0.870). Additionally, AFP ≥ 200 ng/mL and Rim APHE were significantly associated with HCC recurrence (p < 0.05).

CONCLUSIONS: The combinational model, integrating clinical, CT quantitative, and qualitative features, shows potential for the noninvasively preoperative prediction of proliferative HCC. Further validation is needed to establish its broader clinical utility.

KEY POINTS: Question Preoperative identification of proliferative HCC could influence patient treatment and prognosis, yet there is no CT-based universally applicable model to identify this subtype. Findings The updated standard 2021 LI-RADS universal lexicon-based features, in combination with quantitative MDCT measurements, could aid in the noninvasive detection of proliferative HCC. Clinical relevance The updated standard 2021 LI-RADS universal lexicon-based CT qualitative features and quantitative measurements may aid in identifying proliferative HCC and tumor recurrence, offering potential guidance for personalized treatment. Further studies are required to assess their generalizability to different clinical scenarios.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Zhang W, Li N, Li J, et al. Noninvasive identification of proliferative hepatocellular carcinoma on multiphase dynamic CT: quantitative and LI-RADS lexicon-based evaluation. Eur Radiol. 2024. PMID: 39665988. doi:10.1007/s00330-024-11247-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。